Heron Therapeutics, Inc. (HRTX)

Heron Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-20.2	-13.58	-110.56	-182.02	-220.68
Depreciation & Amortization	2.31	2.49	2.9	2.89	3.02
Stock-Based Compensation	10.34	12.96	32.85	42.98	46.85
Other Adjustments	11.83	3.2	-0.77	-0.25	2.54
Change in Receivables	-10.71	-18.74	-8.09	-16.55	6.35
Changes in Inventories	-31.05	-11.05	12.46	-6.19	-6.48
Changes in Accounts Payable	-2.72	8.47	0.02	-0.58	3.28
Changes in Accrued Expenses	11.72	3.65	-3.03	11.8	-29.85
Changes in Other Operating Activities	0.88	-9.93	15.43	1.01	-8.39
Operating Cash Flow	-27.59	-22.53	-58.79	-146.91	-203.35
Capital Expenditures	-0.32	-1.71	-1.55	-1.83	-3.02
Sale of Property, Plant & Equipment	0.1	0.03	0.01	0.23	0.03
Purchases of Investments	-50.79	-103.09	-87.66	-145.68	-129.22
Proceeds from Sale of Investments	67.01	123.48	107.19	143.96	164.94
Investing Cash Flow	16.01	18.71	18	-3.32	32.73
Long-Term Debt Issued	137.25	-	24.35	-	148.96
Long-Term Debt Repaid	-150	-	-	-	-
Net Long-Term Debt Issued (Repaid)	-12.76	-	24.35	-	148.96
Issuance of Common Stock	19.32	0.94	29.76	75.06	7.07
Net Common Stock Issued (Repurchased)	19.32	0.94	29.76	75.06	7.07
Issuance of Preferred Stock	7.86	-	-	-	-
Net Preferred Stock Issued (Repurchased)	7.86	-	-	-	-
Financing Cash Flow	14.43	0.94	54.11	75.06	156.03
Net Cash Flow	2.85	-2.88	13.31	-75.18	-14.6
Free Cash Flow	-27.91	-24.24	-60.33	-148.74	-206.38
FCF Margin	-18.02%	-16.80%	-47.49%	-138.14%	-239.01%
Free Cash Flow Per Share	-0.17	-0.16	-0.44	-1.37	-2.10
Levered Free Cash Flow	-52.13	-21.65	-59.98	-174.92	-113.15
Unlevered Free Cash Flow	-21.72	-19.6	-84.38	-167.55	-259.26

Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q